Colossal Biosciences, the genetics company known for its ambitions to bring back extinct creatures, has secured backing from the Trump administration for an initiative aimed at preserving genetic material from endangered wildlife. Addressing an audience at a public technology forum, Chief Executive Officer Ben Lamm explained the strategic rationale behind engaging with the White House, asserting that facing dire environmental outlooks means one cannot simply bury their head in the sand for four years.
Conservation Concerns and Biobanking Strategy
The collaboration comes despite an administration that has historically shown little enthusiasm for traditional land and wildlife preservation policies. Conservation specialists have raised sharp concerns about Colossal partnering with the Trump administration earlier this year on the biobanking project. Critics contend that elevating future de-extinction programs diverts vital focus from shielding existing species from extinction right now. The concern is that if policymakers believe science can resurrect lost animals later, urgency around habitat preservation and anti-poaching measures today might decline. Lamm argued that collecting and banking genetic samples has become indispensable as climate degradation and loss of natural habitats accelerate pressure on global biodiversity.
Surging Valuation, Spinoffs, and Working Dogs
Colossal secured $230 million in its Series C funding round last year, an influx of capital that established its market valuation at $10.2 billion. The biotechnology venture is now in talks to assemble another capital round, seeking a valuation ranging between $20 billion and $30 billion. Beyond its flagship prehistoric targets, the startup has launched several spinoff enterprises. One spinoff utilizes engineered microbes to break down plastic waste. Colossal also holds an equity stake in Warhound, a specialized venture developed by Lamm alongside Anduril Chief Executive Officer Palmer Luckey. Warhound aims to engineer genetically enhanced dogs tailored for law enforcement, military operations, and emergency response teams. Lamm noted that this initiative applies biobanking principles to cut reliance on commercial puppy mills producing working canines in Europe.
Mammoth Timeline Slips and Scientific Scrutiny
Public attention has surrounded Colossal for claims involving the creation of woolly mice and efforts to reconstruct dire wolves as stepping stones toward resurrecting the woolly mammoth. Independent scientists and critics, however, have questioned whether the venture emphasizes publicity over core scientific substance. When the company unveiled its dire wolves, scientific observers pointed out that their genomic architecture remains remarkably close to modern gray wolves. David Jachowski, a professor at Clemson University, noted that defining distinct species inherently involves an element of subjectivity. Lamm acknowledged that Colossal will miss its initial 2028 target for producing a woolly mammoth, even though researchers have completed 130 specific modifications to mammoth genes. He added that he is unbothered whether critics label the animals gene-edited gray wolves or refer to forthcoming mammoths as hairy elephants.
Future Announcements and Leaving Ocean Predators Alone
Despite persistent skepticism regarding promotional hype, Lamm maintained that Colossal has actually understated its technical progress in genome editing, promising further major milestones that will surprise the public. He drew a firm boundary, however, at prehistoric marine apex predators. Despite heavy public interest urging the company to consider reviving the giant prehistoric shark megalodon, Lamm made it clear that such projects are entirely off the table, humorously observing that the ocean is already terrifying enough without them.
